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Hemicrania continua ( HC) was described and coined by Sjaastad and Spierings in 1984. Later cases, carrying this
appellation should, grossly, conform to this original description. The proposed classification criteria (ICHD, 3rd
edition beta version) for HC has major shortcomings, and ordinary HC cases do not fulfill the proposed criteria.
Relatively rare symptoms and signs are e.g. made obligatory (point C 1). And the recommended dosage of
indomethacin- both test and long-term dosages-is unallowably high. In this way, bogus HC cases are systematically
created. This irrational diagnostic system is in urgent need of a major revision.
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This memorandum concerns the new IHS criteria
(ICDH- 3 beta) for Hemicrania continua. We recently
wrote a note about this [1]. Goadsby responded [2].
Goadsby entitles his response: “Hemicrania continua—
building on experience and clinical science”. In contra-
distinction to what others do? –The response as well as
the diagnostic criteria themselves are largely based on a
previous article by Goadsby [3]. This research may in it-
self have serious shortcomings. In this context, we will,
therefore, scrutinize it.Indomethacin
On top of a combination of unilaterality and chronicity
of the head pain, a positive indomethacin test is required
to ensure the Hemicrania continua (HC) diagnosis. It is,
therefore, of the utmost importance that this test is con-
ducted correctly –and also that the continuation treat-
ment is streamlined. Antonaci l6 years ago [4] introduced
the “INDO- test”, with a strict regimen and sober doses.
The standard dosage was 50 mg i.m. If no definitely posi-
tive response followed, another trial with 100 mg indo-
methacin i.m. would be carried out. The gross difference
between the two dosages was not so much a difference in
degree of response, since both gave a total response; what* Correspondence: ellhed @ online.no
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in any medium, provided the original work is pseparated them was rather a constant difference in time
prior to response, the larger dosage having the shortest re-
action time. A 50 mg test dosage, therefore, generally
sufficed.
Goadsby used the test many years later [3], but for un-
known reasons (or was it perhaps to get some kind of
priority also to this type of activity?), the test dosage was
manipulated with: 100-200 mg, i.m., were used. Since
50 mg generally is an adequate dosage, these dosages
were accordingly 2-4 times as high as necessary. It goes
without saying that the dosage should be as low as pos-
sible; indomethacin is a potentially harmful drug.
In a review study carried out by our group [5], the mean
daily oral dose for indomethacin continuation treatment
was 83 mg orally and the range: 50-150 mg. The corre-
sponding figures in Goadsby’s series [3] were 176 mg and
25-500 mg. In other words, in the latter study [3], the
mean continuation dosage was more than doubled. A total
of 42% of Goadsby’s patients [3] used a continuation
dosage higher than the highest allowable daily oral
dosage, i.e. > 200 mg, against no one in our review [5].
The dosage that is necessary to combat pain of
indomethacin-responsive headaches, is actually relatively
low. The extra dosage used in the cited study [3] is with-
out rational basis. Such dosages may do harm, e.g. create
side effects - even headache. In addition, they may have
some general analgesic, but unspecific effects upon other
headaches, headaches that are unrelated to HC. Head-
aches, needing high indomethacin dosages, are not HCis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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of practice, this activity should be abandoned.
But the situation is worse than this: The uncritical ma-
nipulation with indomethacin dosages in all probability
underlies the misfortune concerning the clinical part of
the study [3]. The high indomethacin dosages will lead
to the birth of fake positive cases.
Clinical symptoms
In the C 1 part of the criteria, under letters a-g, a heap
of phenomena are listed, such as: forehead/facial
sweating and sensation of fullness in the ear. These
phenomena are generally taken directly from the clin-
ical study [3]. Several of these specific features were
also present in our review [5], i.e. 6 of them. However,
the incidence of each of them, e.g. sweating, was strik-
ingly lower in our group. The ratios between the fre-
quencies of the single items in Goadsby’s study [3] and
our [5] ranged from 2.6 to 6.7. The mean ratio was 4.4.
Further, in our review [5], there was a female/ male ra-
tio of 5.0 (15: 3); in Goadsby’s study, the corresponding
figures were: 1.6 and (24:16).
In biology, these are tremendous differences. Already
here the alarm bells should have sounded. Since the
difference is so marked and systematic, it has an inher-
ent meaning. In theory, this could have to do with the
patient groups studied or with the indomethacin test
itself. Small differences can exist between solitary HC
patients and consequently also between members of a
cohort, but not systematic differences of this magni-
tude. The different outcomes have to do with the indo-
methacin test itself and with the human factor linked
to it. The indomethacin dosage has primarily been
tampered with; consequently, a lot of wilderness- has
been popping up, OUTSIDE the HC frame. The ensu-
ing high number of bogus symptoms and bogus cases
makes the material more or less useless and unsuited
as source of information concerning HC.
Throbbing occurred in 69% of the patients (presented
elsewhere, in: [3]).
Behavioral phenomena, like restlessness during at-
tack and pain aggravation by movement were oc-
casionally encountered, in our review [5]. Such
phenomena were given diagnostic prominence among
the Goadsby diagnostic criteria, i.e. point C2. Also in
this respect, there is a huge difference between the
two series, although this difference is not so easily
quantified.
Goadsby [2] used a statement by O. S. from1987 [6]
to the effect that it would be acceptable over time to
add new features to this picture. This statement is in
full agreement with our present view. However, our
statement cannot serve as an excuse for the extensive
changes made by Goadsby in the HC criteria proposal.What was foreseen by us at the time were alterations
WITHIN the frame of HC- not changes entirely out-
side it.
There are two other, major- actually destructive- short-
comings in the new diagnostic system, destructive in
connection with this categorization activity: C1 and C2
are made OBLIGATORY, although being developments
outside the frame of HC.
The very existence of occasional HC cases that in
addition to the basic symptomatology present e.g. con-
junctival injection or nasal stuffiness, does not allow a
policy that make these phenomena obligatory. This
misunderstanding is actually fundamental. If one
wanted to point out that there in HC also can be lacri-
mation etc., one could easily have made a footnote,
with the message: such symptoms are consistent with
HC. Another matter of not inconsiderable importance:
We have termed patients with a HC-like picture, but
non-influenced by indomethacin: “Non-indomethacin
responsive chronic hemicrania”, or: NIRCH. Goadsby’s
reply: “Non” is not an option. Really? We all observe
such cases. How shall they then be categorized? Should
such headache not have been mentioned in the new
categorization? For the time being, this headache
seems to be similar to HC, except for the lack of indo-
methacin response, and the single word: “Non” can do
the trick, again for the time being. “NON” exists in
many word combinations: non-conformism and: non-
sense. It is recommended that “NIRCH” should be
used.
Goadsby wrote: “I would submit the diagnosis has
not changed—” [2]. That is a meaningless and unin-
formative statement in this situation, completely out of
context. The term is the same: Hemicrania continua. It
is the contents of the term that have changed, the
downhill course being initiated- and continued- by
Goadsby.—And -still- the references to the original
works by Antonaci [4] and Sjaastad/Spierings [7]
should be added.
If these new criteria were to be adopted, at least one
of the two original patients [7] will have to be excluded;
cases that made us observant of this group of patients.
The female patient enjoyed close to pain freedom ever
thereafter [8], with regular indomethacin dosages. This
is a sinister part of the story. The situation is simply like
this: either the original frame of this disorder is wrong-
or the new criteria are wrong. The alternative that both
are correct, does not exist. There are two indomethacin-
responsive headaches, and she did not have CPH !As
pointed out in detail by us [1], this situation must be
attended to. In his response, Goadsby does not even
touch this problem. We are here at the heart of the
problem. Goadsby will simply have to respond, also to
this specific question.
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